...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

I realize that there are many possibilities and further thinking also makes me wonder if this is just teaming up with a Chinese partner as it is tough to deal in China without a Chinese partner. That doesn't change that one of our members posted a year ago that he had been told there was a sale coming and I have received from totally other sources that something similar was coming and should have happened by now but hasn't and probably isn't close. I hope I am wrong but I have been here long enough to have witnessed this many times now.

Share
New Message
Please login to post a reply